Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "ELUTIA INC.", but the filing text identifies the registrant as Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2021
Reporting Period: Quarter ended September 30, 2021
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Global Market under the symbol "AZYO". This filing serves to announce financial results for the third quarter of 2021 via a press release incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2021, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the full text of the press release regarding the financial results is furnished as Exhibit 99.1 and incorporated by reference. No specific commentary, guidance, or outlook is detailed in the cover text.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in this report (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that Section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the actual financial figures (Revenue, Net Loss, Cash Position) by reviewing Exhibit 99.1 (Press Release dated November 9, 2021), as they are not present in the cover document.
- Confirm the company name discrepancy: The filing is for Aziyo Biologics, Inc., not "ELUTIA INC." as noted in the request metadata.
- Review the press release for any updates on clinical trial progress or operational milestones, which are typical for biotechnology firms but not detailed in this summary text.
- Check the "Emerging Growth Company" status implications on financial reporting standards as indicated by the checked box in the filing.